PL205544B1 - Preformulacja farmaceutyczna do tabletkowania zawierająca sprzężone końskie estrogeny oraz sposób jej wytwarzania - Google Patents
Preformulacja farmaceutyczna do tabletkowania zawierająca sprzężone końskie estrogeny oraz sposób jej wytwarzaniaInfo
- Publication number
- PL205544B1 PL205544B1 PL368730A PL36873002A PL205544B1 PL 205544 B1 PL205544 B1 PL 205544B1 PL 368730 A PL368730 A PL 368730A PL 36873002 A PL36873002 A PL 36873002A PL 205544 B1 PL205544 B1 PL 205544B1
- Authority
- PL
- Poland
- Prior art keywords
- formulation
- pharmaceutical
- range
- estrogens
- mesh size
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 169
- 229940035811 conjugated estrogen Drugs 0.000 title claims abstract description 71
- 238000009472 formulation Methods 0.000 title claims description 84
- 239000000284 extract Substances 0.000 claims abstract description 104
- 229940088597 hormone Drugs 0.000 claims abstract description 89
- 239000005556 hormone Substances 0.000 claims abstract description 89
- 238000000034 method Methods 0.000 claims abstract description 72
- 239000000262 estrogen Substances 0.000 claims abstract description 66
- 229940011871 estrogen Drugs 0.000 claims abstract description 62
- 239000007787 solid Substances 0.000 claims abstract description 47
- 241000283073 Equus caballus Species 0.000 claims abstract description 34
- 239000000126 substance Substances 0.000 claims abstract description 23
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 55
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 54
- 239000003937 drug carrier Substances 0.000 claims description 50
- 239000002245 particle Substances 0.000 claims description 48
- 239000007864 aqueous solution Substances 0.000 claims description 41
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 40
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 40
- 239000004480 active ingredient Substances 0.000 claims description 31
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 30
- 239000008101 lactose Substances 0.000 claims description 30
- 239000013543 active substance Substances 0.000 claims description 25
- DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 claims description 22
- 229960003399 estrone Drugs 0.000 claims description 22
- 210000002700 urine Anatomy 0.000 claims description 22
- VOXZDWNPVJITMN-SFFUCWETSA-N 17α-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-SFFUCWETSA-N 0.000 claims description 21
- WKRLQDKEXYKHJB-UHFFFAOYSA-N Equilin Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3=CCC2=C1 WKRLQDKEXYKHJB-UHFFFAOYSA-N 0.000 claims description 19
- WKRLQDKEXYKHJB-HFTRVMKXSA-N equilin Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4C3=CCC2=C1 WKRLQDKEXYKHJB-HFTRVMKXSA-N 0.000 claims description 19
- 239000002904 solvent Substances 0.000 claims description 19
- DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 claims description 18
- 238000005507 spraying Methods 0.000 claims description 17
- 238000009826 distribution Methods 0.000 claims description 16
- 239000012141 concentrate Substances 0.000 claims description 15
- 238000001035 drying Methods 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 238000012216 screening Methods 0.000 claims description 8
- 238000005029 sieve analysis Methods 0.000 claims description 8
- 239000003960 organic solvent Substances 0.000 claims description 7
- QTTMOCOWZLSYSV-QWAPEVOJSA-M equilin sodium sulfate Chemical compound [Na+].[O-]S(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4C3=CCC2=C1 QTTMOCOWZLSYSV-QWAPEVOJSA-M 0.000 claims description 6
- 239000010419 fine particle Substances 0.000 claims description 6
- NLLMJANWPUQQTA-SPUZQDLCSA-N estra-1,3,5(10),7-tetraene-3,17alpha-diol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@@H](CC4)O)[C@@H]4C3=CCC2=C1 NLLMJANWPUQQTA-SPUZQDLCSA-N 0.000 claims description 5
- VUCAHVBMSFIGAI-ZFINNJDLSA-M estrone sodium sulfate Chemical compound [Na+].[O-]S(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 VUCAHVBMSFIGAI-ZFINNJDLSA-M 0.000 claims description 5
- 229910052708 sodium Inorganic materials 0.000 claims description 5
- 239000011734 sodium Substances 0.000 claims description 5
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 4
- 150000001298 alcohols Chemical class 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 229930182834 17alpha-Estradiol Natural products 0.000 claims description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 3
- NHTBIADYQKCUHK-CMZLOHJFSA-M [Na+].C[C@]12CC[C@H]3[C@@H](CCc4cc([O-])ccc34)[C@@H]1CC[C@@H]2O Chemical compound [Na+].C[C@]12CC[C@H]3[C@@H](CCc4cc([O-])ccc34)[C@@H]1CC[C@@H]2O NHTBIADYQKCUHK-CMZLOHJFSA-M 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- CZFNZYFVJFYZML-AMGVKYAUSA-M sodium;[(9s,13s,14s,17r)-17-hydroxy-13-methyl-6,9,11,12,14,15,16,17-octahydrocyclopenta[a]phenanthren-3-yl] sulfate Chemical compound [Na+].[O-]S(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@@H](CC4)O)[C@@H]4C3=CCC2=C1 CZFNZYFVJFYZML-AMGVKYAUSA-M 0.000 claims description 2
- 238000012545 processing Methods 0.000 abstract description 12
- 238000012360 testing method Methods 0.000 description 30
- 239000003125 aqueous solvent Substances 0.000 description 15
- 239000003826 tablet Substances 0.000 description 14
- 239000007921 spray Substances 0.000 description 11
- 229920003084 Avicel® PH-102 Polymers 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 239000000969 carrier Substances 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 239000011159 matrix material Substances 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 235000019888 Vivapur Nutrition 0.000 description 6
- 239000000825 pharmaceutical preparation Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 239000007858 starting material Substances 0.000 description 6
- 239000013563 matrix tablet Substances 0.000 description 5
- 229920013685 Estron Polymers 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 239000006286 aqueous extract Substances 0.000 description 4
- 239000002956 ash Substances 0.000 description 4
- PDRGHUMCVRDZLQ-UHFFFAOYSA-N d-equilenin Natural products OC1=CC=C2C(CCC3(C4CCC3=O)C)=C4C=CC2=C1 PDRGHUMCVRDZLQ-UHFFFAOYSA-N 0.000 description 4
- PDRGHUMCVRDZLQ-WMZOPIPTSA-N equilenin Chemical compound OC1=CC=C2C(CC[C@]3([C@H]4CCC3=O)C)=C4C=CC2=C1 PDRGHUMCVRDZLQ-WMZOPIPTSA-N 0.000 description 4
- 229960005309 estradiol Drugs 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 3
- 238000000889 atomisation Methods 0.000 description 3
- 239000004202 carbamide Substances 0.000 description 3
- 125000000853 cresyl group Chemical class C1(=CC=C(C=C1)C)* 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- HVDGDHBAMCBBLR-UHFFFAOYSA-N enterolactone Chemical compound OC1=CC=CC(CC2C(C(=O)OC2)CC=2C=C(O)C=CC=2)=C1 HVDGDHBAMCBBLR-UHFFFAOYSA-N 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 238000000227 grinding Methods 0.000 description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 229960000747 sodium estrone sulfate Drugs 0.000 description 3
- -1 sulphate salt Chemical class 0.000 description 3
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 239000003463 adsorbent Substances 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- 238000010924 continuous production Methods 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- LMJQCTISQYSLPF-JOWXCZTESA-M sodium;[(8r,9s,13s,14s,17r)-17-hydroxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-3-yl] sulfate Chemical compound [Na+].[O-]S(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 LMJQCTISQYSLPF-JOWXCZTESA-M 0.000 description 2
- 238000001694 spray drying Methods 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- OUGSRCWSHMWPQE-WMZOPIPTSA-N (13s,14s)-3-hydroxy-13-methyl-7,11,12,14,15,16-hexahydro-6h-cyclopenta[a]phenanthren-17-one Chemical compound OC1=CC=C2C(CC[C@]3([C@H]4CCC3=O)C)=C4CCC2=C1 OUGSRCWSHMWPQE-WMZOPIPTSA-N 0.000 description 1
- 206010003439 Artificial menopause Diseases 0.000 description 1
- HVDGDHBAMCBBLR-PBHICJAKSA-N Enterolactone Chemical compound OC1=CC=CC(C[C@H]2[C@@H](C(=O)OC2)CC=2C=C(O)C=CC=2)=C1 HVDGDHBAMCBBLR-PBHICJAKSA-N 0.000 description 1
- 235000002918 Fraxinus excelsior Nutrition 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010027304 Menopausal symptoms Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- IVPYDRYLQPJSBW-UBDQQSCGSA-N [(9s,13s,14s,17s)-17-hydroxy-13-methyl-6,9,11,12,14,15,16,17-octahydrocyclopenta[a]phenanthren-3-yl] hydrogen sulfate Chemical compound OS(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4C3=CCC2=C1 IVPYDRYLQPJSBW-UBDQQSCGSA-N 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000007907 direct compression Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000002706 dry binder Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- GRXPVLPQNMUNNX-MHJRRCNVSA-N estrane Chemical compound C1CC2CCCC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CCC[C@@]1(C)CC2 GRXPVLPQNMUNNX-MHJRRCNVSA-N 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 238000002657 hormone replacement therapy Methods 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 239000006082 mold release agent Substances 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 239000012088 reference solution Substances 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
- A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01129840 | 2001-12-14 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| PL368730A1 PL368730A1 (en) | 2005-04-04 |
| PL205544B1 true PL205544B1 (pl) | 2010-04-30 |
Family
ID=8179550
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL368730A PL205544B1 (pl) | 2001-12-14 | 2002-12-12 | Preformulacja farmaceutyczna do tabletkowania zawierająca sprzężone końskie estrogeny oraz sposób jej wytwarzania |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US8273728B2 (enExample) |
| EP (1) | EP1458363B1 (enExample) |
| JP (1) | JP4695838B2 (enExample) |
| CN (2) | CN100502839C (enExample) |
| AR (1) | AR037642A1 (enExample) |
| AU (1) | AU2002358682B2 (enExample) |
| BR (1) | BR0214954A (enExample) |
| CA (1) | CA2470209A1 (enExample) |
| ES (1) | ES2403218T3 (enExample) |
| MX (1) | MXPA04005767A (enExample) |
| PL (1) | PL205544B1 (enExample) |
| TW (1) | TWI332400B (enExample) |
| WO (1) | WO2003051337A1 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9586335B2 (en) * | 2010-01-27 | 2017-03-07 | Sd3, Llc | Blade guard with dust collection |
| TWI332400B (en) * | 2001-12-14 | 2010-11-01 | Solvay Pharm Gmbh | Preformulation for the tableting of natural mixtures of conjugated estrogens |
| US8349819B2 (en) | 2002-10-09 | 2013-01-08 | Dr. Reddy's Laboratories New York, Inc. | Steroid extraction process from urine sources |
| US6992075B2 (en) * | 2003-04-04 | 2006-01-31 | Barr Laboratories, Inc. | C(14) estrogenic compounds |
| US8497258B2 (en) | 2005-11-12 | 2013-07-30 | The Regents Of The University Of California | Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract |
| US20090232897A1 (en) * | 2008-03-14 | 2009-09-17 | Bijayananda Sahoo | Pharmaceutical compositions comprising conjugated estrogens |
| WO2010144865A2 (en) | 2009-06-12 | 2010-12-16 | Meritage Pharma, Inc. | Methods for treating gastrointestinal disorders |
| CA2768452A1 (en) * | 2009-07-16 | 2011-01-20 | Avantor Performance Materials, Inc. | Material and process for incorporation of low dosage active pharmaceutical ingredients and use thereof |
| US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| RS62297B1 (sr) | 2011-11-23 | 2021-09-30 | Therapeuticsmd Inc | Prirodne kombinovane hormonske supstitucione formulacije i terapije |
| EP2787987B1 (de) * | 2011-12-08 | 2016-06-01 | Hexal AG | Neue pharmazeutische statin-zusammensetzung |
| US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
| US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
| US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
| US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| JP2017516768A (ja) | 2014-05-22 | 2017-06-22 | セラピューティックスエムディー インコーポレーテッドＴｈｅｒａｐｅｕｔｉｃｓｍｄ， Ｉｎｃ． | 天然の併用ホルモン補充療法剤及び療法 |
| US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
| US10286077B2 (en) | 2016-04-01 | 2019-05-14 | Therapeuticsmd, Inc. | Steroid hormone compositions in medium chain oils |
| US9931349B2 (en) | 2016-04-01 | 2018-04-03 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical composition |
| US11633405B2 (en) | 2020-02-07 | 2023-04-25 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical formulations |
| US20210246928A1 (en) * | 2020-02-11 | 2021-08-12 | Carl Chasse | Fastener having improved wobble control, fastening system including the same, and method of forming the same |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3487152A (en) * | 1967-02-07 | 1969-12-30 | Hoffmann La Roche | Tablets containing 7 - chloro - 2 - methylamino - 5 - phenyl - 3h - 1,4 - benzodiazepine-4-oxide and conjugated estrogenic substances |
| US4154820A (en) | 1976-02-23 | 1979-05-15 | Akzona Incorporated | Compositions containing alkali metal sulfate salts of conjugated estrogens and antioxidants as stabilizers |
| DE3535536A1 (de) * | 1985-10-04 | 1987-04-09 | Lentia Gmbh | Verfahren zum gleichzeitigen trocknen und granulieren von extraktstoffen aus enteiweisstem kaelberblut |
| EP0322020A1 (en) * | 1987-12-22 | 1989-06-28 | Akzo N.V. | Pharmaceutical dosage unit for treating climacteric complaints and osteoporosis |
| WO1997004752A1 (en) * | 1995-07-26 | 1997-02-13 | Duramed Pharmaceuticals, Inc. | Pharmaceutical compositions of conjugated estrogens and methods for their use |
| ATE264110T1 (de) | 1996-08-30 | 2004-04-15 | Solvay Pharm Gmbh | Prozess zur gewinnung von oestrogenen aus stutenharn |
| DK0923381T3 (da) | 1996-08-30 | 2004-05-10 | Solvay Pharm Gmbh | Fremgangsmåde til fremstilling af östrogener ud fra hoppeurin |
| US6200289B1 (en) | 1998-04-10 | 2001-03-13 | Milestone Scientific, Inc. | Pressure/force computer controlled drug delivery system and the like |
| JP2000156938A (ja) | 1998-11-19 | 2000-06-06 | Hokuto Denko Kk | 電池の充放電試験装置 |
| TWI332400B (en) * | 2001-12-14 | 2010-11-01 | Solvay Pharm Gmbh | Preformulation for the tableting of natural mixtures of conjugated estrogens |
-
2002
- 2002-11-29 TW TW091134752A patent/TWI332400B/zh not_active IP Right Cessation
- 2002-12-04 AR ARP020104698A patent/AR037642A1/es unknown
- 2002-12-12 CA CA002470209A patent/CA2470209A1/en not_active Abandoned
- 2002-12-12 CN CNB2006101684418A patent/CN100502839C/zh not_active Expired - Fee Related
- 2002-12-12 PL PL368730A patent/PL205544B1/pl unknown
- 2002-12-12 MX MXPA04005767A patent/MXPA04005767A/es active IP Right Grant
- 2002-12-12 CN CNB028262077A patent/CN1298313C/zh not_active Expired - Fee Related
- 2002-12-12 WO PCT/EP2002/014104 patent/WO2003051337A1/de not_active Ceased
- 2002-12-12 EP EP02792980A patent/EP1458363B1/de not_active Expired - Lifetime
- 2002-12-12 AU AU2002358682A patent/AU2002358682B2/en not_active Ceased
- 2002-12-12 BR BR0214954-0A patent/BR0214954A/pt not_active IP Right Cessation
- 2002-12-12 ES ES02792980T patent/ES2403218T3/es not_active Expired - Lifetime
- 2002-12-12 JP JP2003552270A patent/JP4695838B2/ja not_active Expired - Fee Related
-
2004
- 2004-06-14 US US10/866,095 patent/US8273728B2/en not_active Expired - Fee Related
-
2012
- 2012-05-30 US US13/483,530 patent/US8329679B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| PL368730A1 (en) | 2005-04-04 |
| CN100502839C (zh) | 2009-06-24 |
| CN1298313C (zh) | 2007-02-07 |
| TW200408400A (en) | 2004-06-01 |
| CN1607944A (zh) | 2005-04-20 |
| HK1075007A1 (en) | 2005-12-02 |
| CA2470209A1 (en) | 2003-06-26 |
| CN1977862A (zh) | 2007-06-13 |
| ES2403218T3 (es) | 2013-05-16 |
| AU2002358682A1 (en) | 2003-06-30 |
| JP4695838B2 (ja) | 2011-06-08 |
| AU2002358682B2 (en) | 2009-03-26 |
| BR0214954A (pt) | 2004-12-14 |
| JP2005516923A (ja) | 2005-06-09 |
| US20120237666A1 (en) | 2012-09-20 |
| US8329679B2 (en) | 2012-12-11 |
| EP1458363B1 (de) | 2013-01-16 |
| HK1104220A1 (zh) | 2008-01-11 |
| WO2003051337A1 (de) | 2003-06-26 |
| MXPA04005767A (es) | 2004-09-10 |
| AR037642A1 (es) | 2004-11-17 |
| US8273728B2 (en) | 2012-09-25 |
| TWI332400B (en) | 2010-11-01 |
| EP1458363A1 (de) | 2004-09-22 |
| US20050009800A1 (en) | 2005-01-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL205544B1 (pl) | Preformulacja farmaceutyczna do tabletkowania zawierająca sprzężone końskie estrogeny oraz sposób jej wytwarzania | |
| JP4841092B2 (ja) | フェノフィブレート含有医薬組成物およびこれを調製するための方法 | |
| RU2627111C2 (ru) | Таблетка, содержащая дегидроэпиандростерон (дгэа) | |
| JPH10505846A (ja) | 湿式粒状化による投与単位体を製造する方法 | |
| RU2207133C2 (ru) | Стабилизированные композиции тиболона | |
| JP4695837B2 (ja) | 複合エストロゲン天然混合物を調節して放出するマトリックス−被膜錠剤 | |
| CA2275626C (en) | Homogeneous preformulations containing high concentrations of steroids, for producing low-dose solid and semi-solid pharmaceutical preparations | |
| ZA200200380B (en) | Low-dose tablets and preparation process. | |
| HK1104220B (en) | Pre-formulation for the tabletting of natural mixtures of conjugated estrogens | |
| CZ24798A3 (cs) | Způsob přípravy pevných dávkových forem s velmi nízkou dávkou léčiva, farmaceutický prostředek a použití | |
| HK1075005B (en) | Matrix film tablets for the controlled release of natural mixtures of conjugated estrogen | |
| HK1075007B (en) | Pre-formulation for the tabletting of natural mixtures of conjugated estrogens | |
| EP1767194A1 (de) | Verfahren zur Herstellung von Adsorbaten des Drospirenons |